Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Multicenter Double-blind Randomized Study of Taletrectinib Versus Placebo in Patients With ROS1-Fusion Positive Stage IB-IIIA Non-Small Cell Lung Cancer Who Have Undergone Complete Tumor Resection

NCT07154706 is registered in ClinicalTrials.gov with Nuvation Bio Inc. as lead sponsor.

NCT NCT07154706
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07154706 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Multicenter Double-blind Randomized Study of Taletrectinib Versus Placebo in Patients With ROS1-Fusion Positive Stage IB-IIIA Non-Small Cell Lung Cancer Who Have Undergone Complete Tumor Resection
Lead sponsor
Nuvation Bio Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
August 21, 2025
Completion date
August 30, 2033
Enrollment
180 (estimated)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer (nsclc)